Senseonics (NYSE:SENS) shares are up today on Q4 earnings ahead of the consensus forecast, with the company planning to launch its next-gen, implantable, 6-month CGM in the U.S next month. The Germantown, Maryland-based company posted revenues of $4 million for the three months ended Dec. 31, 2021, representing sales growth of 2.6% from the same […]
Senseonics
Ascensia launches Senseonics’ remote monitoring app for Android devices in Europe
Ascensia Diabetes Care announced today that it launched Senseonics‘ (NYSE:SENS) Eversense NOW remote monitoring app for Androids in Europe. The launch makes remote monitoring capabilities available for all of Senseonics Eversense and Eversense XL continuous glucose monitoring (CGM) users on Android and iOS operating systems in the U.S. and Europe, respectively. Get the full story at our […]
Senseonics wins FDA approval for next-generation Eversense 180-day CGM, provides 2022 outlook
Senseonics (NYSE:SENS) announced today that the FDA approved its next-generation continuous glucose monitor system, which lasts up to half a year. Germantown, Maryland–based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days). Senseonics previously offered the system with a 90-day wear time. Data […]
With FDA clearance ‘imminent’ for Senseonics 180-day CGM, what’s next?
When Dr. Fran Kaufman began her career in the late 1970s, diabetes management consisted of urine testing and animal insulin. At that point, it had not been proven that managing glucose actually mattered, according to Kaufman, and proof didn’t come until 1992 with the conclusion of the DCCT study. “I’ve seen a lot of innovation,” […]
Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’
Senseonics (NYSE:SENS) announced that it anticipates the FDA to decide within weeks on approval of its new CGM system. The company seeks a premarket approval supplement for the next-generation Eversense 180-day implantable continuous glucose monitoring (CGM) system. Data presented earlier this year demonstrated strong accuracy. The next-generation Eversense matched performance levels compared to the current […]
Senseonics wins CE mark for remote glucose monitoring app for Android users
Senseonics (NYSE:SENS) announced today that its Eversense NOW remote monitoring app for Android received CE mark approval. Germantown, Maryland–based Senseonics already received such approval for the Eversense NOW iOS platform and can now offer it in Europe on the Android operating system. The company expects to make the Eversense NOW remote monitoring app for Android available […]
7 diabetes treatment innovations to look out for on World Diabetes Day
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in […]
Senseonics posts Q3 earnings beat, hopes for new FDA approval soon
Senseonics (NYSE:SENS) shares ticked up slightly on third-quarter results that beat the consensus earnings forecast. The Germantown, Maryland-based company posted profits of $42.9 million, or 8¢ per share, on sales of $3.5 million for the three months ended Sept. 30, 2021, for a massive bottom-line swing out of the red on sales growth of nearly $3 […]
MedTech 100 roundup: Hot streak comes to slight halt
After several weeks of high-level performance, the medtech industry saw its first dip in a while over the last seven days. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 13) at 117.92 points, marking a –1.2% dip from the 119.41-point tally a week prior […]
Senseonics slides on earnings miss in Q2
Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus earnings forecast. The Germantown, Md.-based diabetes management technology developer posted losses of –$180.3 million on sales of $3.3 million for the three months ended June 30, 2021, seeing its bottom line plummet from losses of just –$7.5 million this time last year. […]
Senseonics touts new next-gen Eversense CGM data
Senseonics (NYSE:SENS) today presented further positive data evaluating its next-generation Eversense continuous glucose monitoring system. Germantown, Md.–based Senseonics presented data from the Promise study at the American Diabetes Association Virtual 81st Annual Scientific Sessions. The data adds to positive results already presented by the company at the beginning of this month that demonstrated high levels […]